HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hanley, J P Search for Related Content PubMed PubMed Citation Articles by Hanley, J P Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB WARFARIN

Warfarin reversal

Correspondence to:
Dr J P Hanley
Department of Haematology, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne NE1 4LP, UK; john.hanley{at}nuth.northy.nhs.uk
ABSTRACT
Warfarin is the most commonly used oral anticoagulant in the UK. It is associated with few side effects apart from haemorrhage. The most appropriate way to reverse the anticoagulant effect of warfarin depends on the clinical circumstances. In serious bleeding, rapid reversal is required, whereas in minor bleeding or asymptomatic over anticoagulation, a more leisurely approach is usually appropriate. This review discusses the current approaches to warfarin reversal in clinical practice. The development of a uniform approach to warfarin reversal in the Northern Region is described.

Abbreviations: FFP, fresh frozen plasma; ICH, intracranial haemorrhage; INR, international normalised ratio; IV, intravenous; NRHG, Northern Region Haematologists’ Group; PCC, prothrombin complex concentrate; rFVIIa, recombinant activated factor VII

Keywords: haemorrhage; prothrombin complex concentrate; vitamin K; warfarin

This article has been cited by other articles:

				M. A. Crowther and T. E. Warkentin Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents Blood, May 15, 2008; 111(10): 4871 - 4879. [Abstract] [Full Text] [PDF]

				M. L. Flaherty, B. Kissela, D. Woo, D. Kleindorfer, K. Alwell, P. Sekar, C. J. Moomaw, M. Haverbusch, and J. P. Broderick The increasing incidence of anticoagulant-associated intracerebral hemorrhage Neurology, January 9, 2007; 68(2): 116 - 121. [Abstract] [Full Text] [PDF]

				S. B. Lee, E. M. Manno, K. F. Layton, and E. F.M. Wijdicks Progression of warfarin-associated intracerebral hemorrhage after INR normalization with FFP. Neurology, October 10, 2006; 67(7): 1272 - 1274. [Abstract] [Full Text] [PDF]

				H. B. Huttner, P. D. Schellinger, M. Hartmann, M. Kohrmann, E. Juettler, J. Wikner, S. Mueller, U. Meyding-Lamade, R. Strobl, U. Mansmann, et al. Hematoma Growth and Outcome in Treated Neurocritical Care Patients With Intracerebral Hemorrhage Related to Oral Anticoagulant Therapy: Comparison of Acute Treatment Strategies Using Vitamin K, Fresh Frozen Plasma, and Prothrombin Complex Concentrates Stroke, June 1, 2006; 37(6): 1465 - 1470. [Abstract] [Full Text] [PDF]

				J. C. Hemphill III Treating Warfarin-Related Intracerebral Hemorrhage: Is Fresh Frozen Plasma Enough? Stroke, January 1, 2006; 37(1): 6 - 7. [Full Text] [PDF]

				T. Steiner, J. Rosand, and M. Diringer Intracerebral Hemorrhage Associated With Oral Anticoagulant Therapy: Current Practices and Unresolved Questions Stroke, January 1, 2006; 37(1): 256 - 262. [Abstract] [Full Text] [PDF]